HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Machiyo Ishigaki Selected Research

Cdc25C phosphatase (211-221)

10/2011CBP501-calmodulin binding contributes to sensitizing tumor cells to cisplatin and bleomycin.
1/2007Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Machiyo Ishigaki Research Topics

Disease

2Neoplasms (Cancer)
10/2011 - 01/2007
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
10/2011
1Malignant Mesothelioma
10/2011

Drug/Important Bio-Agent (IBA)

2Cdc25C phosphatase (211-221)IBA
10/2011 - 01/2007
2DNA (Deoxyribonucleic Acid)IBA
10/2011 - 01/2007
1Bleomycin (Blenoxane)FDA LinkGeneric
10/2011
1Cisplatin (Platino)FDA LinkGeneric
10/2011
1PlatinumIBA
10/2011
1Doxorubicin (Adriamycin)FDA LinkGeneric
10/2011
1Pharmaceutical PreparationsIBA
10/2011
1Fluorouracil (Carac)FDA LinkGeneric
10/2011
1Phosphotransferases (Kinase)IBA
01/2007
1Antineoplastic Agents (Antineoplastics)IBA
01/2007